Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glyburide + fluconazole + rifampin
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
glyburide + fluconazole + rifampin is a drug combination used in a Phase 1 pharmacokinetic drug-drug interaction study conducted by the University of California, San Francisco. The study investigated the complex effects of metabolic and transporter-mediated interactions on glyburide, a second-generation sulfonylurea used for type 2 diabetes mellitus. Glyburide works by inhibiting ATP-sensitive potassium channels in pancreatic beta cells to stimulate insulin release. Fluconazole acts as a CYP2C9 inhibitor, while rifampin serves as both an acute inhibitor of hepatic uptake transporters (OATP) and a chronic inducer of CYP2C9 enzymes. This research aimed to understand how these co-administered drugs alter glyburide exposure and its glucose-lowering efficacy.
- Other names
- glyburide + fluconazole + rifampin-University of California, San Francisco-type 2 diabetes mellitus
02
Targets
KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on glyburide + fluconazole + rifampin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glyburide + fluconazole + rifampin.